Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the European Patent Office has decided to grant a patent covering the use of the company's stem cell secretions technology for the topical treatment of acne.
In late May, members of the executive team visited Japan to advance discussions with potential manufacturing and commercial partners for Progenza in Japan. We are pleased to report our meetings went well and we are on track to enter into our first significant partnering agreement in Japan by the end of September 2016.
Regeneus Ltd (ASX:RGS) announce that an investment report by Edison titled "Potential Japan licence deal a STEP closer" has been published on the Regeneus website.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced the Australian Research Council (ARC) had awarded a Linkage Grant of $340,000 to a research consortium that includes Regeneus collaborating with leading researchers from Macquarie University and the University of Adelaide.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of enrolment of all 20 patients in the STEP trial. Further, a review of the cumulative study safety data by the study safety oversight committee identified no safety concerns.
The Life Sciences Report: Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Regeneus Ltd (ASX:RGS) Achieved better than targeted net operating cash flow for the quarter. Cash outflow for the quarter was $1.44 million. Cash flow is tracking consistently better than the target of $1.70 million per quarter.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported financial results and operational highlights for the 6 month period ended 31 December 2015.
Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing cell-based therapies to treat unmet medical needs with a focus on osteoarthritis and other musculoskeletal disorders and oncology diseases for both humans and animals.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of a review of safety from the first cohort of 10 patients in the STEP trial.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
